UCLA researchers in the Department of Orthopaedic Surgery have developed a novel method to generate mesodermal precursors from human pluripotent stem cells to treat chronic skeletal muscle atrophy and fibrosis.
Cell based therapy has shown great promise in treating human muscle atrophy and fibrosis. Mesodermal progenitor cells provide a plentiful, precisely identified cell source that can be reproducibly induced to produce desired therapeutic cells. However, there is a shortage of suitable cell sources for the derivation of mesodermal progenitor cells, and cell sources greatly impact the differentiation and therapeutic efficiency of the drive progenitor cells. There is an unmet need to derive mesodermal progenitor cells of high quality and sufficient quantity.
UCLA researchers in the Department of Orthopaedic Surgery have developed a novel method to derive mesodermal cells that will be sufficient for effective treatment of human muscle injury. A single step protocol is used to for generation of mesodermal cells from human pluripotent stem cells with 90% efficiency. Expansion of the derived cells resulted in a 104-fold increase in cell number within few weeks, without any additional cell sorting or isolation. When the derived mesodermal stem cells were injected in a murine muscle injury model, the numbers of diseased atrophic muscle myofibers significantly decreased.
human stem cell, cell therapy, muscle atrophy, fibrosis, mesodermal progenitor cells, embryonic stem cells, protocol